HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.4%

Neg 0% Neu 88.4% Pos 0%

HC Wainwright & Co. analyst Matthew Keller reiterates GRI Bio (NASDAQ:GRI) with a Buy and maintains $10 price target.

Comments

No comments yet. Be the first!